Recent Patents on Drug Delivery & Formulation

Ryan F. Donnelly
School of Pharmacy
Queen's University Belfast
Belfast
UK

Back

The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

Author(s): Irina Kadiyala and Dylan Jacobs

Affiliation: Vertex Pharmaceuticals Incorporated, Department of Formulation Development, 130 Waverly St., Cambridge, MA 02139-4242.

Keywords: Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine, oral delivery, pentasa.

Abstract:

This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®, Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 8
ISSUE: 1
Page: [3 - 11]
Pages: 9
DOI: 10.2174/18722113113079990014